Krystal Biotech, Inc.

The company discovers, manufactures, and commercializes redosable genetic medicines designed to treat rare and debilitating conditions with substantial unmet medical needs. Utilizing a proprietary gene therapy platform engineered from herpes simplex virus-1, it produces targeted therapies that can be administered non-invasively at healthcare facilities or in home environments. Its principal commercial offering is Vyjuvek, an approved topical treatment for wounds caused by dystrophic epidermolysis bullosa. In addition to developing pipeline candidates for respiratory, dermatological, and ophthalmic diseases, the business addresses aesthetic conditions through its dedicated subsidiary, primarily serving pediatric and adult patients affected by serious genetic disorders.

The company operates two commercial-scale manufacturing sites situated in Pennsylvania, from which it distributes gene therapies internationally. Commercial activities are conducted directly across the United States, Japan, and major European markets including Germany and France, alongside planned expansions into broader Western European territories. It further distributes products via regional specialty partner networks in Central and Eastern Europe, the Middle East, and Israel. The provided text mentions no details regarding the location of the corporate headquarters.

Summary of the business section of Krystal Biotech's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

“As of February 11, 2026, we had 295 full-time employees, primarily engaged in research and development, pre-clinical and clinical trials, manufacturing VYJUVEK and our pipeline product candidates, commercial activities for VYJUVEK in the United States, the European Union, and Japan, regulatory matters, strategic business development, finance and other t”